Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563670 | 1.00 | TSHR (0.40) | TSHRCA2MEN1ALDH1A1KMT2A | |
| SCHEMBL10226156 | 1.00 | TSHR (0.40) | TSHRCA2MEN1ALDH1A1KMT2A | |
| SCHEMBL564459 | 1.00 | TSHR (0.40) | TSHRCA2MEN1ALDH1A1KMT2A | |
| SCHEMBL18244712 | 1.00 | TSHR (0.40) | TSHRCA2MEN1ALDH1A1KMT2A | |
| SCHEMBL31115609 | 1.00 | TSHR (0.40) | TSHRCA2MEN1ALDH1A1KMT2A | |
| SCHEMBL40199 | 1.00 | TSHR (0.40) | TSHRCA2MEN1ALDH1A1KMT2A | |
| SCHEMBL1394152 | 0.97 | — | — | |
| SCHEMBL15803984 | 0.86 | TSHR (0.48) | TSHRMEN1ALDH1A1KMT2A | |
| SCHEMBL12360400 | 0.86 | TSHR (0.48) | TSHRMEN1ALDH1A1KMT2A | |
| SCHEMBL31324014 | 0.86 | TSHR (0.48) | TSHRMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12161760-B2 | Implantable particles and related methods | SIGILON THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12084517-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| US-20210188897-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOF | SPARX THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188897-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOF | SPARX THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-7429581-B2 | Pyrazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| EP-1581523-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
| EP-1097142-B1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | disclosed |
| US-6492360-B1 | Phthalazine derivatives phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-12-10 | — | — | US | disclosed |
| US-6329370-B1 | CARDIOVASCULAR DISORDERS AND TUMOR NECROSIS FACTOR (HEREINAFTER TNF.SUB..ALPHA.), A CYTOKINE WITH PRO-INFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2001-12-11 | — | — | US | disclosed |
| EP-1097142-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000005218-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | TSHR 823/4885CA2 1493/4885MEN1 1660/4885 |
| US-20210188897-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOF | NR3C2, CRH, CYP17A1 | TSHR 1035/4885CA2 3662/4885MEN1 483/4885 |
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | TSHR 4176/4885CA2 2364/4885MEN1 1313/4885 |
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | F12, F5, F11 | TSHR 353/4885CA2 3743/4885MEN1 1497/4885 |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | F11, F5, F12 | TSHR 739/4885CA2 3482/4885MEN1 2588/4885 |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | TSHR 4176/4885CA2 2364/4885MEN1 1313/4885 |
| US-12161760-B2 | Implantable particles and related methods | TNNT2, TNNI3, TNNC1 | TSHR 1686/4885CA2 3003/4885MEN1 733/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TSHR 2359/4885CA2 1661/4885MEN1 3001/4885 |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | TSHR 1686/4885CA2 3003/4885MEN1 733/4885 |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | TSHR 4176/4885CA2 2364/4885MEN1 1313/4885 |
| US-12084517-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | TSHR 4176/4885CA2 2364/4885MEN1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.